Raise closed, search for fresh raises on Seedstage

Brooklyn, NY

Innovating early cancer detection through advanced DNA-based testing methods.

• Mission: Transforming early cancer detection through innovative DNA-based biomarker identification to improve patient outcomes and accessibility.  
• Innovation: Utilizing a groundbreaking diagnostic testing platform that delivers faster and more accurate results than traditional methods, with results available in as little as six hours.  
• Market Opportunity: Positioned to capture growth in the U.S. Cancer Diagnostics Market, leveraging emerging demand for faster and more reliable cancer detection solutions.  
• Affordability and Accessibility: Offering an affordable testing solution aimed at broadening access to early cancer detection for a wider population.  
• Leadership: Led by a team of experts with extensive scientific backgrounds, including CEO Michael Marquardt, positioning the company to drive advancements in cancer diagnostics.  
• Strategic Impact: Aiming to reduce the fear and uncertainty surrounding cancer diagnoses by enabling earlier, more accurate detection, improving treatment outcomes.

Epi One is focused on transforming the landscape of early cancer detection through its innovative DNA-based biomarker identification methods, which aim to provide faster and more accurate results than current market offerings.

With the U.S. Cancer Diagnostics Market projected to experience significant growth in the coming years, Epi One is strategically positioned to leverage this opportunity. The company, led by a team of experts including CEO Michael Marquardt and co-founders with extensive scientific backgrounds, has already secured early angel funding and is preparing to launch its groundbreaking diagnostic testing platform.

This platform is designed to detect cancer at an early stage, thereby increasing the chances of successful treatment and reducing the fear associated with cancer diagnoses. Epi One’s commitment to accuracy and affordability reflects its mission to improve patient outcomes and make early cancer detection accessible to a broader population.

As the company moves towards commercialization, it seeks to raise additional funds to further its research and development efforts, ultimately aiming to make a significant impact in the field of cancer diagnostics and patient care.

Company Info

Epi One provides innovative blood tests for early and accurate cancer diagnosis.

Epi One is a company focused on improving cancer diagnosis through innovative technology. Their approach aims to provide early and accurate cancer detection using a simple blood test. Traditional cancer screening methods often involve lengthy wait times for results and can be costly and imprecise. Epi One’s technology utilizes DNA-based biomarker identification to deliver results in as little as six hours, which can significantly increase the chances of successful treatment and survival for patients. The test is designed to be affordable, costing around $500 per patient, and aims to enhance the overall efficiency of cancer diagnosis and monitoring. By addressing the challenges associated with conventional screening methods, Epi One seeks to make a meaningful impact on cancer outcomes worldwide.